Medikura

What Medikura does

Medikura is a Munich-based digital health company founded in 2017 that develops communication software for pharmaceutical companies. The company operates the brite™ platform, a one-stop-shop digital health solution that connects pharmaceutical and medical device manufacturers with patients through digital therapy companions, expert-validated educational content, real-world patient data collection, and digitized pharmacovigilance workflows. The platform architecture pairs a general indication-related content area (co-developed with Charité Berlin and other research institutes) with proprietary product-specific spaces for each pharma partner spanning OTC, prescription (RX), and medical device (MP) categories.

The business model is enterprise SaaS subscription, sold on an annual, quote-based cadence with a direct enterprise field sales motion led by a Chief Client Officer. Distribution combines direct sales to pharma manufacturers with channel partnerships through healthcare professional associations (notably the German Federal Association of Pulmonologists) and pharmacy networks. The platform serves 25+ named pharmaceutical partners including Pfizer, Novo Nordisk, Moderna, Vertex, Gilead, Grünenthal, and AAA-Pharma, addressing pain points such as the 50% patient non-compliance rate, 60% information deficit, and the cost burden of standalone patient apps (claimed 90% savings versus proprietary development). In April 2026, the company closed a €4 million funding round led by Fil Rouge Capital to accelerate European expansion beyond its primary German market.

Name

Medikura

Legal name

XO Life GmbH

Website

https://medikura.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Munich-based digital health company developing communication software for pharmaceutical companies, offering the brite platform that connects pharma and medical device manufacturers with patients via digital therapy companions, real-world data collection, pharmacovigilance digitization, and expert-validated educational content.

Ownership category

akta.pro rank

Product category

Digital Health Platform

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

akta.pro secondary industry

DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Digital patient engagement
• Pharma communication software
• Digital therapy support
• Real world patient data
• Pharmacovigilance digitization

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Platform Licensing / SaaS Subscription: Pharmaceutical and medical device manufacturers subscribe to the brite platform to access digital patient support capabilities for their product portfolio. Each manufacturer receives its own dedicated product spaces on the platform. Pricing is likely subscription-based though not publicly disclosed.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Medikura develops the brite platform, a one-stop-shop digital health SaaS solution that enables pharmaceutical and medical device manufacturers to provide patients with digital product and treatment support. The platform combines a general indication-related content area (co-developed with leading research institutes such as Charité) with proprietary product-specific spaces covering OTC, RX, and medical device categories, and integrates publishing, therapy support, real-world data, and pharmacovigilance capabilities within a single application.

Product overview

XO Life offers the brite™ platform, a unified digital health platform that provides pharmaceutical and medical device manufacturers with multiple integrated solutions for patient engagement. The platform architecture consists of a general indication area (co-developed with research institutes like Charité) providing standardized patient experiences, combined with proprietary product spaces for OTC, prescription (RX), and medical device (MP) products. The platform integrates four core solution areas: publish content for expert positioning, product/treatment support, Real World Data collection, and pharmacovigilance digitization—all accessible from a single application.

Differentiator

Problem solved

Functional benefit

Brands

• brite™: Digital patient support and treatment support platform connecting pharma with patients

Products and services

• brite Platform A globally unique one-stop-shop digital patient support platform that connects pharmaceutical and medical device manufacturers with patients to provide digital product and treatment support, featuring a general indication-related content area (co-developed with Charité and other leading research institutes) and proprietary product-specific spaces covering OTC, RX, and medical device categories.

Quantifiable outcome

• 60% of patients have information deficits about their own treatment — brite addresses this with expert-validated educational content
• +3 more outcomes

Named customers20 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and supporting.

• German Federal Association of Pulmonologists (Bundesverband der Pneumologen)coreStrategic or Co-development Partner · 2 June 2026Following a successful pilot, brite™ was launched nationwide in Germany through the Federal Association of Pulmonologists. Pulmonologists actively refer asthma and COPD patients to the brite digital therapy support platform, providing a direct patient referral channel. This partnership enables free access to digital treatment support for patients across Germany.
• Charité BerlincoreStrategic or Co-development PartnerCharité, one of Europe's leading university hospitals, collaborates with XO Life on the general indication-related content area of the brite platform. The research institute contributes expert-validated educational content about illnesses and treatments, lending scientific credibility to the platform.
• Münster UniversitysupportingStrategic or Co-development PartnerProfessor Dr. Dr. Bettina Pfleiderer from Münster University serves on XO Life's expert advisory network, contributing academic and clinical expertise to the platform's content and development.
• BridgehöpfesupportingStrategic or Co-development PartnerBridgehöpfe (founders Jürgen Graalmann and Matthias Suermondt) is a strategic partner contributing expertise from the German health insurance and pharmaceutical PR sectors. Jürgen Graalmann is ex-CEO of AOK (Germany's largest health insurer) and Matthias Suermondt is ex-PR head at Sanofi.
• m.DocsupportingStrategic or Co-development Partnerm.Doc (CEO Admir Kulin) is a digital health company providing smart healthcare solutions. CEO Admir Kulin serves on XO Life's expert network, contributing expertise in digital health platform deployment.
• AescuvestsupportingStrategic or Co-development PartnerAescuvest is a digital health investment platform founded by Dr. Patrick Pfeffer (ex-MD of WebMD Germany). Dr. Pfeffer serves on XO Life's expert network, contributing investment and market intelligence expertise to the platform's strategy.
• Helmholtz Center MunichsupportingStrategic or Co-development PartnerProfessor Dr. med. Jörg Hasford from Helmholtz Center Munich served on XO Life's expert advisory network, contributing expertise in medical research and clinical practice to the platform.
• RWTH Aachen UniversitysupportingStrategic or Co-development PartnerMarius Rosenberg, MD and startup excellence expert from RWTH Aachen University, serves on XO Life's expert network, contributing academic and clinical expertise.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• XO Life (brite platform): Closely related Munich-based digital health platform offering the brite platform for pharma patient engagement, digital therapy companions, RWE collection, and pharmacovigilance digitization. Directly comparable product offering and customer base, and likely the most relevant peer given the apparent ecosystem relationship.
• Click Therapeutics: Prescription digital therapeutics company developing software-based treatments in partnership with pharma (e.g., Otsuka). Directly comparable as a pharma-partnered digital therapeutics / therapy companion platform targeting the same regulatory and commercial dynamics.
• Voluntis (AptarGroup): Digital therapeutics platform historically focused on patient companion apps for oncology, diabetes, and rare diseases in partnership with pharma (Sanofi, AstraZeneca). A relevant comparable in pharma-embedded digital therapy support, now part of AptarGroup.
• WellDoc: Digital health platform offering prescription digital therapeutics and patient engagement tools integrated with pharma and payer channels. Comparable as a smaller-scale DTx vendor competing for similar pharma digital-patient-engagement budgets.
• S3 Connected Health: Specializes in digital therapeutics, connected device programs, and patient engagement platforms for pharma and medtech clients across Europe. Directly comparable European digital health vendor with similar pharma-software focus.

Broad incumbents

• IQVIA: Global life sciences technology and analytics leader offering patient engagement, real-world evidence, and pharmacovigilance solutions to pharma manufacturers. Represents the scaled incumbent that Medikura competes against in enterprise pharma digital health RFPs.
• Veeva Systems: Enterprise cloud software provider for the life sciences industry with patient-centric, CRM, and clinical data solutions used by most large pharma companies. Relevant broad incumbent for pharma-vertical software targeting the same buyer personas.
• mySugr (Roche): Diabetes patient engagement and digital therapy platform acquired by Roche. A relevant incumbent comparable for pharma-embedded patient companion apps and RWE capture in chronic conditions.

Emerging players

• Medisafe: Digital medication adherence and patient engagement platform used by pharma for branded companion apps. Comparable in pharma patient-engagement software but with stronger consumer/medication-adherence positioning.

Regional players

• Ada Health: Berlin-based AI-driven symptom assessment and patient engagement platform with pharma partnerships. Comparable European digital health company with pharma B2B revenue motion and AI-enabled patient tools.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/medikura
• LinkedInlinkedin.com/company/medikura

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medikura